{
  "Q0": "Whole exome sequencing (WES)",
  "Q1": "Yes",
  "Q2": "Yes",
  "Q3": "No",
  "Q4": "No",
  "Q5": "Not specified",
  "Q6": "No",
  "Q7": "No",
  "Q8": "Yes",
  "Q8_alternative_test": "No specific alternative test is named in the policy, but the policy only covers specific targeted pharmacogenetic and pharmacodynamic tests for defined drug indications, not broad exome sequencing.",
  "Q9": "Not specified",
  "Q10": "No",
  "Q10_purpose": "Diagnostic",
  "Q11": "Not specified",
  "Q12": "No",
  "Q13": "Not specified",
  "Q14": "Not listed",
  "Q15": "No",
  "Q16": "No",
  "Q17": "The policy does not provide a process for submitting claims for whole exome sequencing (WES) in this context, as WES is not listed as a covered service. Only specific, targeted pharmacogenetic and pharmacodynamic tests for defined drug indications are considered medically necessary. Claims for WES would be denied as experimental, investigational, or unproven for this clinical scenario.",
  "match": false
}